Serina Therapeutics Inc (SER) Stock Forecast
SER analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $9.50 average of analyst targets
- Upside to target
- +452.3% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $1.28 – $5.26
SER analyst ratings
1 analystsNumber of analysts at each rating.
SER price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SER earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.37 | −$0.31 | −$0.45 | +24.4% | 2 |
| Current fiscal year (2026) | −$1.58 | −$1.76 | −$1.40 | −$1.91 | +17.3% | 2 |
| Next fiscal year (2027) | −$1.16 | −$1.33 | −$0.98 | −$1.58 | +26.9% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SER revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
SER EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SER EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.46 | −$0.49 | −$0.49 | −$0.34 | −$0.34 | −26.1% | 2 up · 0 down |
| Current fiscal year (2026) | −$1.84 | −$1.95 | −$1.95 | −$1.58 | −$1.58 | −14.1% | 2 up · 0 down |
| Next fiscal year (2027) | −$1.26 | −$1.57 | −$1.57 | −$1.16 | −$1.16 | −8.3% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SER earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SER beat in 3 of 7.
What analysts expect from SER
1 analysts cover Serina Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.50, 452.3% above the latest close of $1.72. Analysts expect earnings of −$1.58 per share for 2026, +17.3% from a year earlier. For 2027 the average estimate is −$1.16 per share. Serina Therapeutics beat the EPS estimate in 3 of the last 7 quarters.
Related: SER income statement, SER key metrics, SER chart. See the SER stock overview for the latest quote and news.
SER forecast FAQ
What is Serina Therapeutics's price target?
The average analyst price target for Serina Therapeutics is $9.50, 452.3% above the latest close of $1.72.
Is Serina Therapeutics a buy, hold or sell?
Of 1 analysts covering Serina Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Serina Therapeutics's EPS forecast?
Analysts forecast −$1.58 per share for 2026 (range −$1.76 to −$1.40); for 2027 the estimate is −$1.16.
When does Serina Therapeutics report earnings?
Serina Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Serina Therapeutics usually beat earnings estimates?
Serina Therapeutics reported EPS at or above the analyst estimate in 3 of the last 7 quarters.